HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PBH

Prestige Consumer Healthcare Inc. (NYSE)

Healthcare — Drug Manufacturers - Specialty & Generic

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

None 5 analysts
$48.16
+$0.89 (+1.88%)
Target: $66.80 (38.7%)
Sign in to add PBH to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$2.28B
P/E Ratio (TTM)12.32
Forward P/E9.50
EPS (TTM)$3.91
Dividend Yield-
Profit Margin17.48%
Revenue Growth-5.00%
ROE10.22%
Debt/Equity55.39
Recommendation None
Analyst Target$66.80
Analysts5
Indexes NYSE

Technical Indicators

RSI (14)46.7
Beta0.35
SMA 20-
SMA 40-
52-Week High$80.69
52-Week Low$42.62
50-Day Avg$49.99
200-Day Avg$59.33
Avg Volume708.2K
Volume386.7K

Performance Analysis

NEUTRAL

PBH presents a mixed picture with both positive and negative indicators.

~ Trading at 15% of its 52-week range.
~ RSI at 46.7 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ P/E of 12.3 suggests the stock may be undervalued.
- Revenue declined 5.0% year-over-year.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $66.80 implies 38.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:25 UTC

Back to Screener Export Report